Hillstream BioPharma Operating Income

The latest operating income for HILS is $-54M as of June 2026. That compares with $-14M in the prior-year period — down 290.5% year over year. Investors often review this figure alongside Hillstream BioPharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, HILS's operating income moved from $-14M to $-54M — a 290.5% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Hillstream BioPharma's operating scale or balance-sheet position.

A operating income figure of $-54M for HILS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting HILS's operating income ($-54M), review year-over-year change from $-14M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.